Regenerative medicine is a breakthrough treatment option for an increasing number of clinical conditions. It can cure some types of leukemia, significantly improve chronic conditions like cartilage defects or malignant melanomas, and can even be used to construct organ parts, including blood vessels and skin.

Nonetheless, this revolution in medicine raises many questions and hurdles. In our study "Regenerative Medicine – The next generation of therapeutic products is set to shake up the pharmaceutical world" we outline how pharmaceutical companies can prepare themselves for the coming transformation.

By strengthening their "innovation radar" and scouting capabilities, reviewing their research and development and commercial models, establishing a supply chain for regenerative medicine, training physicians, as well as developing digital services to support the use of the new products and generate real-life data, Big Pharma can ensure that it will not be left behind.